이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Green Cross Wellbeing’s cancer cachexia drug gets clinical trial nod from Germany

Collected: 2017.12.21

Distributed: 2017.12.22

Source: Go Direct

South Korea’s Green Cross Wellbeing said on Tuesday German health authorities BfArM has approved a phase 2 clinical trial of its investigational drug BST204 for the treatment of patients with cancer cachexia. Cancer cachexia is a wasting syndrome characterized by weight loss and systemic weakness due to the growth of cancer cells in the body. There is no treatment available for this debilitating condition.

Active ingredient of BST204 is ginsenoside, a natural energy stimulant which helps to increase energy metabolism and muscular activity. Efficacy was validated in a preclinical trial and safety was proven in a phase I study conducted in Germany, according to the company. The proposed clinical research will be conducted in three university hospitals across Germany in 150 patients with lung cancer and colorectal cancer.

BST204 is being evaluated with a treatment goal initially in patients with lung cancer and colorectal cancer and later in different cancer types, the company said. The company also said it considers partnership with a global pharmaceutical company after the ongoing clinical trial comes to an end successfully.

By Shin Chan-ok and Minu Kim

Read in Korean

List

Previous: Korea’s exports up 16.4% on yr in Dec 1-20, surplus at $2.1 bn

Next: Doosan Robotics starts mass production of cobots